Several non-invasive tests have been developed for the diagnosis of bladder outlet obstruction (BOO) in men to avoid the burden and morbidity associated with invasive urodynamics. The diagnostic accuracy of these tests, however, remain uncertain.
Introduction
Lower urinary tract symptoms (LUTS) are prevalent and bothersome in men and women of all ages. Determining whether these symptoms are due to bladder outflow obstruction (BOO) is important in determining the optimal management (1) . Indeed, the success rate from surgical procedures, such as transurethral resection of the prostate, is presumed to be superior in patients with urodynamically documented BOO. However, it is not possible to reliably diagnose BOO based on clinical symptoms alone, and the gold standard for diagnosis is by urodynamic assessment with a pressure-flow study. However, this is an invasive test with risks of bothersome urinary symptoms, haematuria and urinary tract infection. Furthermore, it can be unpleasant, with considerable rates of anxiety and embarrassment (2) . It also requires dedicated equipment and specific expertise, and is expensive. Consequently, a number of non-invasive tests have been described to replace the pressure-flow study in diagnosing BOO in men with LUTS. The objective of this systematic review is to determine the diagnostic accuracy of non-invasive tests in diagnosing BOO in men with LUTS with reference to the gold standard, invasive urodynamics.
Evidence acquisition
We used standard methods recommended by the Cochrane Methods Group for the Systematic Review of Screening and Diagnostic Tests (3), Preferred Reporting Items for Systematic Reviews (PRISMA), and Standards for Reporting Diagnostic Accuracy Studies (STARD) (4). The study protocol was published on PROSPERO (CRD42015019412).
Search strategy
An experienced research librarian (CY) collaborated in planning the search strategy. The EMBASE, MEDLINE, Cochrane Database of Systematic Reviews, Cochrane Central (Cochrane HTA, DARE, HEED), Google Scholar, and WHO international Clinical Trials Registry Platform Search Portal databases were searched up to May 18 th 2016. Only English language articles were included and the detailed search strategy is described in Appendix 1. Additional sources of articles included the reference lists of included studies and clinical content experts (European Association of Urology Male LUTS Guideline Panel). Two reviewers (SM and RU) screened all abstracts and full-text articles independently. Disagreement was resolved by discussion, and where no agreement was reached, a third independent party acted as an arbiter (AKN).
Types of study design included
All types of studies (including at least 10 participants) assessing the diagnostic accuracy of noninvasive tests using invasive urodynamics as a reference standard were eligible.
Types of participant included
Eligible study populations recruited adult men (≥18 years) with LUTS (as defined by the study authors). Studies where the proportion of men with either neurological disease or urethral stricture was higher than 10% were excluded.
Types of intervention included
The following non-invasive tests (i.e. index tests) were eligible for inclusion. A detailed description of each index test is included in Appendix 2.
1. Prostate volume/height 2. Intravesical prostate protrusion (IPP) 3. Detrusor/bladder wall thickness measured on transabdominal ultrasound (DWT/BWT) 4. Ultrasound-estimated bladder weight (UEBW) 5. Doppler ultrasound 6. Near-infrared spectroscopy (NIRS) 7. Uroflowmetry 8. Penile cuff test (PCT) 9. External condom catheter method
Outcome measures
The primary outcome measures for diagnostic accuracy for predicting BOO were sensitivity, specificity, positive predictive value and negative predictive value. Secondary outcome measures included test reliability and reproducibility, adverse events, patient satisfaction, and cost effectiveness as defined by the trial authors, if reported.
Assessment of risk of bias
The risk of bias (RoB) in the included studies was assessed using the QUADAS-2 tool (5). It consists of 4 domains of patient selection, index test, reference standard, and the flow of patients through the study, and timing of the index test and reference standard. RoB was assessed for each domain, and the first 3 domains were also assessed for concerns regarding applicability.
A list of the most important potential confounders for outcomes was developed a priori with clinical content experts (EAU Non-neurogenic Male LUTS guideline panel). The confounder assessment consisted of whether each prognostic confounder was considered and whether, if necessary, the confounder was controlled for in the analysis. The potential confounding factors assessed were: (1) whether indices for pressure flow study were determined automatically or manually; (2) whether the quality of urodynamic study adhered to contemporaneous quality standards (i.e. International Continence Society standards for studies from 2002 onwards; for studies pre-2002, judgement was made by the reviewer and panel member).
Data analysis
Due to the expected heterogeneity in the definitions, thresholds and technical variations of the included index tests, a qualitative (i.e. narrative) synthesis of all included studies was planned. For studies with multiple publications, only the most up-to-date or complete data for each outcome was analysed.
Subgroup analyses were planned for the following groups, if data were available: High vs. low prevalence of BPE, men with a high prevalence of detrusor underactivity (DUA), men with storage versus voiding LUTS, severity of LUTS, men with previous prostate surgery, men treated with medical therapy for storage and/or voiding LUTS, and risk factors for BPE (PSA, Prostate volume, post-void residual.
For each study, the elements of diagnostic accuracy were determined by way of a two-by-two contingency table consisting of true positive (TP), false positive (FP), false negative (FN) and true negative (TN) based on data reported by authors. If there was discrepancy between the observed data (i.e. TP, FP, FN and TN) and derived data (i.e. sensitivity, specificity, positive predictive value and negative predictive value), the observed data took priority, and diagnostic accuracy elements were calculated from the observed data as reported by authors. In addition, descriptive statistics including median and interquartile range, and range, were provided for all diagnostic accuracy elements for each type of index test considered as a whole to provide a summary measure across studies. Sensitivity analysis was planned for each type of index test using the most commonly used threshold values relevant to each test only.
Evidence synthesis

Quantity of evidence identified
The study selection process is outlined in Fig. 1 . A total of 42 studies were eligible for inclusion: 41 non-randomised experimental studies and 1 retrospective comparative study .
Characteristics of included studies
The baseline characteristics of all 42 included studies are shown in Table 1 . A total of 4,444 patients were recruited.
Risk of bias assessment
The summary of methodological quality and RoB assessments is shown in Fig. 2 . The majority of studies had a low RoB in terms of applicability, with most studies including men that are representative of those that would be expected to undergo this test in routine practice. The study by Botkor-Rasmussen included a larger proportion of asymptomatic or minimally-symptomatic men compared to the other studies, and Sullivan et al. included some normal volunteers, which could therefore affect the applicability of the diagnostic test accuracy results obtained (12, 44 The principal source of bias across studies related to the reporting of the reference standard. Although the ICS nomogram is now widely accepted to define BOO on voiding cystometry, a number of studies used different definitions of BOO which may affect the diagnostic accuracy results obtained. Furthermore, some studies classified both equivocal and non-obstructed patients into the same nonobstructed group which may introduce an element of bias into the overall results (6) . In addition to this, blinding to the index test and reference standard was either not clearly discussed or was not performed in a number of studies, again accounting for an unclear or high RoB in data interpretation across studies. In the studies assessing NIRS, the index test and reference standard had to be undertaken simultaneously and so this introduces a RoB with the same investigator analysing the results of both tests at the same time.
The overall RoB across most domains was generally low across most studies, although there was significant heterogeneity of definitions of thresholds, index tests and reference tests.
Narrative synthesis of results
Diagnostic accuracy results
The individual results for each study, organised according to the index test being assessed, are shown in Table 2 . The overall results for each type of index test considered are available in Table 3 . It was not possible to perform subgroup analyses because of lack of data.
Penile cuff test
Seven studies investigated the diagnostic accuracy of the penile cuff test. Overall, diagnostic accuracy was high with a median sensitivity and specificity of 88% and 70%, respectively. There was a low risk of bias across most studies but significant heterogeneity in the threshold values used to diagnose BOO, with 3 studies using the nomogram developed by Griffiths et al. (11, 18, 22) , two using different nomograms (32, 42), and two using a penile urethral compression-release (PCR) index of either 160% or 100% (20, 44). As a result, it is impossible to reliably pool the results of these studies.
Uroflowmetry
Uroflowmetry was assessed in a total of 2,580 patients across 16 studies. Thirteen studies used a cutoff value of 10ml/s to diagnose BOO and reported a median sensitivity and specificity of 68.3% and 70.5%, respectively, with a PPV and NPV of 74.3% and 68% (7, 12, 13, 15, 16, 18, 20, 21, 26, 30, 33, 34, 38, 40, 41) . However, studies varied considerably in their choice of defining variable and cut-off values. The range of sensitivity and specificity values across studies was so wide that no conclusions can be drawn. As would be expected, lowering the cut-off value for Qmax seemed to increase sensitivity at the expense of specificity and vice-versa. But baseline symptom severity also acts as a significant confounder which we are unable to control for with the available data. Overall the diagnostic accuracy of uroflowmetry in diagnosing BOO appears to be relatively limited compared with the other index tests.
Detrusor or bladder wall thickness (DWT/BWT)
DWT was studied in 848 patients across 8 studies (6, 8, 16, 17, 24, 31, 33, 34) , 5 of which used a cutoff of 2mm to define BOO with a high median sensitivity and specificity of 82.7% and 92.6%, respectively, with a PPV and NPV of 90.5% and 85%, respectively. Furthermore, a well-conducted exploratory study reported a cut-off value of 2.9mm as having the best diagnostic value, with a specificity of 100%. Altered DWT and BWT may have a multifactorial basis, and further assessments in well-designed statistically-powered trials are needed to assess wider application in clinical service delivery.
Bladder weight (UEBW)
UEBW was only assessed in 2 studies, both utilising different threshold values to define BOO, and both finding a wide variation in diagnostic accuracy (19, 25) . Therefore, little inference can be made based on the available data on bladder weight.
External condom method
The external condom catheter method was assessed in a single study reporting that up to 73% of patients could be correctly diagnosed with the external condom catheter technique (37). However, from the limited data available it appears that test failure, for various reasons, is a limiting factor.
Intravesical prostatic protrusion (IPP)
IPP was studied in a total of 1,013 patients across 10 studies (6, 8, 9, 13, 15, 17, 23, 28, 36, 39) . Five studies used a cut-off of 10mm to define BOO and overall reported a similar diagnostic accuracy to uroflowmetry alone with a median sensitivity and specificity of 67.8% and 74.8%, with a PPV and NPV of 73.8% and 69.3%. However, threshold values varied, making interpretation difficult.
Doppler ultrasound
Two studies evaluated the role of Doppler ultrasound, one assessing detrusor blood flow and the other assessing urinary flow velocity (10, 35). The small patient numbers render the results on Doppler ultrasound difficult to interpret with any degree of certainty.
Prostate volume and height
Four studies assessed prostate volume or height, and various threshold values were employed, but all of them reported low diagnostic accuracy (16, 17, 28, 45) . NIRS was assessed in 5 studies, 3 of which used the NIRS algorithm to define BOO (14, 29, 43, 46, 47) . Overall diagnostic accuracy was relatively high with a median sensitivity and specificity of 85.7% and 87.5%, respectively. The one study using a mathematical modelling and regression tree algorithm showed the highest diagnostic accuracy (43).
Results for secondary outcomes
Secondary outcomes were not addressed due to the lack of data suitable for a critical analysis.
Discussion
Principal findings
A total of 42 studies recruiting a total of 4,444 patients were eligible for inclusion in this SR, which assessed the diagnostic accuracy of 9 non-invasive tests. There were significant variations among studies investigating the same test, both in terms of the threshold value used to define BOO on the non-invasive test as well as the nomograms used to diagnose BOO on invasive urodynamics. For studies reporting on most commonly used thresholds to define BOO, the penile cuff test using the Griffiths nomogram, DWT > 2mm and the NIRS algorithm had the highest median sensitivities ranging from 82-85.7%. These three tests also had the highest median NPV's of 84-89%. The highest median PPV's were reported for DWT >2mm and the NIRS algorithm, at approximately 90%. The diagnostic accuracy for IPP >10mm was similar to that for a Qmax <10ml/s on free flow rate testing. The studies on IPP also appeared to show that specificity increased with increasing IPSS score, a confounder that would be controlled for in a good prospective trial. The diagnostic ability of the external condom catheter seems promising in the only study included, but this data requires further validation in future studies.
Although the overall RoB was low across many domains for the majority of studies, in many studies, the index test and reference standard were performed unblinded, and in some studies the two tests were performed simultaneously by the same investigator who also analysed the results obtained. This could have potentially biased the interpretation of the findings and final conclusions reached.
Implications for clinical practice
Pressure-flow studies for the evaluation of men with LUTS are often not performed for practical reasons. Several non-invasive techniques have therefore been developed and appear promising in the assessment of men with LUTS. From the evidence reviewed in this paper, the penile cuff test, DWT, UEBW and NIRS have shown the greatest diagnostic accuracy although further validation in studies with more stringent methodological standards are required before they can replace invasive urodynamics. Furthermore, there are a number of factors that need to be considered when discussing generalisability and delivery costs of these tests. The penile cuff test may cause discomfort or urethral bleeding, although this has been reported in only 2% of patients, and technical difficulties have been reported to result in exclusion rates of 23% to 46% (48, 49) . Similarly, the external condom method may also cause discomfort and results may be affected by low flow rates, low voided volumes, and abdominal straining (37). Measurement of DWT and UEBW require specific training and there is a risk of observer error, and NIRS requires specialised equipment. Doppler ultrasound urodynamics suffers from the same limitations of observer error and requires specialised equipment to perform. It is clear that these techniques, either alone or in combination, may be used to aid decision-making and counselling when evaluating men with LUTS in daily clinical practice, especially if invasive urodynamics are unavailable or contra-indicated. However, the quality of the current data is insufficient to recommend the routine use of any non-invasive test over pressure-flow studies in diagnosing BOO in men with LUTS.
How the review compares with previous reviews/guidelines
A number of studies reviewing the evidence for various non-invasive urodynamic tests have been published in recent years (50-57). All reviews have reported similar findings to the present review, reporting that some non-invasive tests appear promising, especially in combination, but further investigation is required before they can replace invasive urodynamics. Importantly, however, the methodology in these reviews differ significantly from the present SR. Primarily, this SR is based on strict inclusion and exclusion criteria with input from a multidisciplinary expert panel to inform the review question. The robust methods used to synthesise the evidence and analyse the data are the principal strengths of this study and therefore provide a more accurate evaluation of the available evidence compared to the other reviews.
Future research
This review has demonstrated that several non-invasive tests seem promising in assessing men with BOO. However, we have highlighted the limitations of the current evidence base in terms of heterogeneity of definitions and threshold values used, and therefore larger studies with more stringent methodological standards are required in order to better assess their role in the evaluation of men with LUTS. The limitations of existing individual tests have led many investigators to assess the role of a combination of tests in improving the diagnostic accuracy for BOO. Although not covered in this SR, the role of combining tests is a promising area that requires further assessment.
Strengths and Limitations
The strengths of this review are the systematic, transparent, and effective approach taken to examine the evidence base, including the use of Cochrane review methodology, the assessment of RoB using QUADAS-2, and adherence to PRISMA and STARD guidelines. The clinical question was prioritised by a multidisciplinary panel of clinical experts, methodologists and patient representative (EAU Nonneurogenic Male LUTS Guideline Panel), and the work was undertaken as part of the panel's clinical practice guideline update for 2016. In addition, the review elements including characteristics of participants, index and reference tests, definitions and thresholds were developed a priori in conjunction with the panel. The search strategy was complemented by additional sources for potentially important articles, including reference lists of included studies and studies identified by the expert panel. This approach ensured a comprehensive review of the literature while maintaining methodological rigour and enabled the authors to put into clinical context the relevance and implications of the review findings. Moreover, the vast majority of studies were prospective in nature, with well-defined index and reference tests, and the overall RoB was generally low across studies. The primary limitation was the large heterogeneity among studies, with regard to definitions of index tests and reference standards. Furthermore, due to lack of data we were unable to perform any subgroup analyses. Another limitation is the basic assumption that invasive urodynamics is a definitive diagnostic investigation for BOO in men. It is known that results of invasive urodynamics and the nomograms based upon pressure-flow studies can have significant inter and intra-investigator variability as well as test-retest variation (58, 59). However, in the absence of a more accurate goldstandard, all studies on these diagnostic tests will continue to be compared to invasive urodynamics. This study has systematically reviewed the evidence assessing the diagnostic accuracy of noninvasive tests in diagnosing BOO in men with LUTS using effective methods of evidence acquisition and synthesis, with input from a multidisciplinary expert panel to inform the review question and review elements. The findings and clinical relevance were interpreted with appropriate clinical context provided by the expert panel. Overall, a number of non-invasive tests appear promising with a low RoB across most domains for the great majority of studies. Limitations of the current evidence base include heterogeneity of definitions and thresholds in regard to index tests and reference standards, and therefore this review has highlighted the need for larger prospective studies with better methodological quality. In spite of these limitations, the findings from this review can help to provide clinical guidance on the accuracy of these tests in daily practice. Therefore, while several tests have shown promising results regarding the non-invasive assessment of BOO, pressure-flow study remains the gold standard test in determining BOO. 
Appendix 2: Detailed description of non-invasive tests included in this review
Penile cuff test
This test involves the placement of a pneumatic cuff around the penile shaft which is inflated on voiding, thereby interrupting flow. The pressure of the resultant fluid column in the urethra is estimated to be intravesical pressure and can be used as a measure of bladder contractility (18).
Uroflowmetry
The patient is asked to urinate into a container which measures the rate and volume of urine voided, and the post-void residual urine volume is then measured with ultrasound. This enables the calculation of the maximum flow rate (Qmax) in ml/s and the flow time, as well as allowing assessment of the patter of flow (60).
3. Detrusor/bladder wall thickness measured on transabdominal ultrasound These tests involve measuring the thickness of the detrusor muscle or entire bladder wall using transabdominal ultrasound. They are based on the findings from animal models and morphological studies that BOO results in detrusor muscle hypertrophy (61, 62), leading to increased BWT and DWT.
Bladder weight
The measurement of ultrasound-estimated bladder weight (UEBW) is based on the same principle as that for BWT or DWT, with bladder weight acting as a measure of detrusor hypertrophy (19).
External condom catheter method
The condom method is another way by which isovolumetric bladder pressure can be measured, and is based on the same principle as the penile cuff tests. The test involves voiding through a condom catheter attached to a valve, and at maximum flow the catheter is occluded and isovolumetric pressure measured via a side-port on the valve (63, 64) .
Intravesical prostate protrusion
The intravesical prostatic protrusion (IPP) is a transabdominal ultrasound-derived measure of prostatic configuration, based on the theory that the prostate protrudes into the bladder as it grows, and therefore leads to BOO as a result of a ball-valve effect (65) .
Doppler ultrasound
This involves the use of Doppler ultrasound to measure detrusor blood flow or velocity of urine flow. It is based on the principle that detrusor blood flow is reduced in patients with BOO and that measuring the detrusor arterial resistive index may be able to predict BOO. Furthermore, by measuring the urinary flow velocity in different parts of the urethra, the velocity ratio can be calculated and may be used to diagnose BOO (10).
Prostate volume/height
This is a transabdominal ultrasound-based measurement of the prostatic configuration.
Near-infrared spectroscopy (NIRS)
This technique involves the measurement of changes in the concentration of oxyhaemoglobin and deoxyhaemoglobin (chromophores) in tissue. It is based on the hypothesis that BOO is associated with a reduction in detrusor blood flow and oxyheamoglobin levels due to the increased work of the detrusor muscle. Consequently, BOO would result in a downward NIRS pattern of slope changes in chromophore concentration whereas an unobstructed system would lead to an upward slope (57).
Table 2. Summary of results for all index tests
Key: BOOI = Bladder outflow obstruction index, BWT = bladder wall thickness, CART = classification and regression tree, DWT = detrusor wall thickness, DAMPF = detrusor-adjusted mean PURR = factor, DAN-PSS = Danish prostatic symptom score, IPSS = International prostate symptom score, LPURR = linear passive urethral resistance relation, NIRS = near-infrared spectroscopy, NR = not reported, NPV = negative predictive value, PCR = penile compression ratio, PPV = positive predictive value, RI = resistive index, UEBW = ultrasound-estimated bladder weight, URA = urethral resistance algorithm, VR = velocity ratio 
